Specificity of the CD66b cell-surface expression upregulation in response to Ags.

<p>(<b>A</b>) Neutrophils (2×10⁶) from allergic patients (n = 10) sensitized to G₃ but not to D₁ and W₆, were incubated with 40 µg/ml protein extracts of G₃, D₁, and W₆ for 24 h. (<b>B</b>) Neutrophils from healthy subject (n = 10) were incubated with 40 µg/ml of T₉, and G₃ for 24 h. CD66b cell-surface expression was measured by flow cytometry. The values shown are the means ± SD.</p

IT downmodulates the levels of CD66b cell-surface expression.

<p>CD66b expression is higher on neutrophils from NLP than those from peripheral blood. (<b>A</b>) Neutrophils (2×10⁶ cells) from healthy subjects (n = 10), non-IT-treated patients with allergic asthma and rhinitis sensitized to G₃ (n = 10), and IT-treated patients with allergic asthma and rhinitis sensitized to G₃ (n = 15) were left untreated (No adds) or treated with G₃ (40 µg/ml) for 24 h. (<b>B</b>) Neutrophils purified from peripheral blood and NLF from non-IT treated patients. The levels of CD66b cell-surface expression were measured by flow cytometry. The values shown are the means ± SD.</p

Measurement of specific antibodies to obeche wood dust.

<p>Means are represented by dotted lines and a horizontal line indicates cut-off value. *p<0.05 symptomatic vs asymptomatics; **p<0.05 symptomatic vs controls. <b>1A</b>. Levels of specific IgE in ORA+, ORA− and CG subjects; <b>1B</b>. Levels of specific IgG in ORA+, ORA− and CG subjects.</p

Demographic characteristics of the study groups.

<p>*Mean±SD.</p><p>**p<0.001, IT-treated group vs non-IT-treated group.</p

CD66 cell-surface expression upregulation in response to Ags is IgE-dependent. IgE receptors involved in the process.

<p>(<b>A</b>) Neutrophils (2×10⁶) from allergic patients sensitized to G₃ (n = 10) were treated, where indicated, to elute the Igs from the cell surface, and then incubated with G₃ (40 µg/ml) or LPS (1 µg/ml) for 24 h, and CD66 cell-surface expression was measured by flow cytometry. Specific IgE and IgG for the above Ags were determined in the elution solution by ELISA. (<b>B</b>) Neutrophils from allergic patients (n = 5) were incubated with anti-FcεRI (CRA 1), anti-CD23 (9P.25) or anti-galectin-3 (A3A12) antibodies at 5 µg/ml for 24 h, and CD66b cell-surface expression was measured as in A. The values shown are the means ± SD.</p

Comparison of demographic and clinical characteristics of the patients evaluated with OAS and GS. Statistical significance is indicated (P).

<p>Comparison of demographic and clinical characteristics of the patients evaluated with OAS and GS. Statistical significance is indicated (P).</p

IT reduces the number of CD66b⁺MPO⁺ cells in NLF.

<p>(<b>A</b>) The percentage of CD66b⁺MPO⁺ cells was analyzed on cells from NLF in healthy subjects (n = 10), IT-treated allergic patients (n = 15) and non-IT-treated allergic patients (n = 10). The values shown are the mean ± SD. (<b>B</b>) Three representative dot-blot of the results shown in A.</p

ELISA inhibition studies in ORA+ subjects.

<p>Bromelain (CCD, solid line) and obeche (dotted line) are inhibitors and obeche extract is the solid phase.</p

CD66b is upregulated from the cell-surface of neutrophils in response to G₃.

<p>(<b>A</b>) Neutrophils (2×10⁶) from allergic patients (n = 10) were left untreated (No adds), treated with LPS (1 µg/ml) or an Ag (G₃) to which the patient was sensitized (40 µg/ml) for 24 h. (<b>B</b>) and (<b>C</b>) Neutrophils from allergic patients (n = 10) were incubated with an Ag (G₃) to which the patient was sensitized for the indicated doses (for 24 h) or times (at a dose of 40 µg/ml), and CD66b cell-surface expression was analyzed by flow cytometry. The results shown are the means ± SD.</p

Demographic and clinical characteristics of subjects with confirmed occupational rhinitis/asthma (ORA+) <i>vs.</i> asymptomatic exposed (ORA−) and controls (CG). SPT: skin prick test; SD: standard deviation; *: p<0.05.

<p>Demographic and clinical characteristics of subjects with confirmed occupational rhinitis/asthma (ORA+) <i>vs.</i> asymptomatic exposed (ORA−) and controls (CG). SPT: skin prick test; SD: standard deviation; *: p<0.05.</p